BioNTech disclosed positive Phase 2 results for trastuzumab pamirtecan (BNT323), setting the stage for an FDA filing as the company looks to compete in HER2-positive oncology where antibody-drug conjugates are gaining share. The company said the Phase 2 readout supports further development in defined patient populations, with additional regulatory steps planned following the data. BioNTech framed the program as a potential alternative to existing HER2 ADC options in subgroups where prior therapies may be limited. The announcement comes as multiple HER2 ADCs vie for space in breast and gastric cancer treatment algorithms, making population-level efficacy and safety details central to how regulators and clinicians interpret the next filing package.